2024 France Hospital Cancer Diagnostics Market

2024 France Hospital Cancer Diagnostics Market: Supplier Shares by Test, Volume and Sales Segment Forecasts for Major Tumor Markers, Competitive Landscape, Innovative Technologies, Instrumentation Review, Opportunities for Suppliers

This new report from contains 533 pages and 43 tables.

The report is available by section, and can be customized to specific information needs and budget.

The report presents a comprehensive analysis of the French hospital cancer diagnostics market, including:

  • Major issues pertaining to the French hospital laboratory practice, as well as key economic, regulatory, demographic, social and technological trends with significant market impact during the next five years.
  • Mortality statistics and scientific views on the etiology of major types of cancer, e.g., lung, colorectal, breast, prostatic, pancreatic, leukemia, lymphoma, gastrointestinal, bladder, liver, ovarian, testicular, oral, skin and others.
  • Test volume and sales forecasts for 40 cancer diagnostic procedures performed in French hospitals.
  • Current instrumentation technologies and feature comparison of leading analyzers.
  • Sales and market shares of & leading suppliers.
  • Emerging diagnostic technologies and their potential market applications.
  • Product development opportunities.
  • Profiles of current and emerging suppliers, including their sales, market shares, product portfolios,& marketing tactics, technological know-how, new products in R&D, collaborative arrangements and business strategies.
  • Business opportunities and strategic recommendations for suppliers.

    Contains 533 pages and 43 tables


    I. Introduction
    II. Worldwide Market Overview
    III. Major Product Development Opportunities
    A. Reagent Kits and Test Systems/Panels
    B. Instrumentation
    C. Computers, Software and Automation
    D. Auxiliary Products
    IV. Design Criteria for Decentralized Testing Products
    V. Alternative Market Penetration Strategies
    A. Internal Development
    B. Collaborative Arrangements
    C. University Contracts
    D. Distribution Strategies
    VI. Potential Market Entry Barriers and Risks
    A. Market Maturity
    B. Cost Containment
    C. Competition
    D. Technological Edge and Limitations
    E. Patent Protection
    F. Regulatory Constraints
    G. Decentralized Testing Market Challenges
    VII. Worldwide Market and Technology Overview
    A. Cancer Statistics and Etiology
    1. Breast Cancer
    2. Lung Cancer
    3. Colon and Rectum Cancer
    4. Prostate Cancer
    5. Stomach Cancer
    6. Leukemia
    7. Lymphoma
    8. Oral Cancer
    9. Skin Cancer
    10. Uterine Cancer
    11. Ovarian Cancer
    12. Bladder Cancer

    B. Major Current and Emerging Cancer Diagnostic Tests
    1. Introduction
    2. Tumor Marker Classification
    3. ACTH
    4. Alpha-Fetoprotein (AFP)
    5. Beta-2 Microglobulin
    6. CA 15-3/27.29
    7. CA 19-9
    8. CA-125
    9. Calcitonin
    10. Carcinoembrionic Antigen (CEA)
    11. Estrogen and Progesterone Receptors
    12. Ferritin
    13. Gastrin
    14. Human Chorionic Gonadotropin (HCG)
    15. Insulin
    16. NSE
    17. Occult Blood
    18. PAP Smear/HPV
    19. Prostatic Acid Phosphatase (PAP)
    20. Prostate-Specific Antigen (PSA)
    21. Squamous Cell Carcinoma Antigen (SCC)
    22. T and B Lymphocytes
    23. TdT
    24. Thyroglobulin
    25. Tissue Polypeptide Antigen (TPA)
    26. Biochemical Tumor Markers
    27. Oncogenes
    - Abl/abl-bcr
    - AIB1
    - BCL-2
    - BRCA1
    - CD44
    - C-fos
    - C-myb
    - C-myc
    - CYP-17
    - Erb-B
    - HPC1
    - N-myc
    - P40
    - P51
    - P53
    - PIK3CA
    - PTI-1
    - Ras
    - Reg

    - Sis
    - Src and others
    28. Polypeptide Growth Factors
    - Basic Fibroblast Growth Factor
    - Beta-TGF
    - Cachectin (TNT)
    - Calmodulin
    - ECFR
    - Nerve Growth Factor (NGF)
    - Epidermal Growth Factor (EGF)
    - Ornithine Decarboxylase
    - Transferrin
    - Transforming Growth Factor-Alpha
    29. Ectopic Hormones
    30. Colony Stimulating Factors
    31. Lymphokines
    - Alpha-Interferon
    - B Cell Growth Factors
    - B Cell Growth Factor (BCGF)
    - Gamma-Interferon
    - Interleukin-1 (IL-1)
    - Macrophage Activating Factor
    32. Immunohistochemical Stains
    33. Emerging Tumor Markers
    - N-Acetylglucosamine
    - Actin
    - Alpha-Actin
    - Antineuronal Antibodies
    - 7B2
    - B72.3
    - Bax
    - BCD-F9
    - BLCA-4
    - Blood Group Antigens A,B,H
    - CA 50
    - CA 72-4/TAG-72
    - CA 195
    - CA-242
    - CA-549
    - CAM 26
    - CAR-3
    - Cathepsin-D
    - Chromogranin A and B
    - Cluster 1 Antigen
    - Cluster-5/5A Antigen
    - CTA
    - CU18
    - DR-70

    - DU-PAN-2
    - Endometrial Bleeding Associated Factor
    - Endostatin
    - Epithelial Membrane Antigen
    - Feulgen Hydrolysis
    - Fibronectin
    - FSH
    - (1->3)-L-fucosyltransferase
    - Gastrin-Releasing Peptide (GRP)
    - GDCFP-15
    - Glucagon
    - Glycoamines
    - H23
    - Her-2
    - Human Carcinoma Antigen
    - HPA
    - HSP27
    - Intermediate Filaments
    - Cytokeratins/CK18/Cyfra 21-1
    - Desmin
    - Gliofibrillary Acid Protein
    - Neurofilaments
    - Vimentin
    - KA 93
    - Kinases
    - KP16D3
    - LAI
    - Leukocyte Common Antigen
    - Lewis Antigens
    - Lysophosphatidic Acid (LPA)
    - Ma 695/Ma 552
    - MABDF3
    - MAG
    - ME1
    - Minactivin
    - MN/CA9
    - MSA
    - Mucin Cancer Antigen (MCA)
    - Multiple Tumor Suppressor 1
    - Myosin
    - NEA-130
    - NMP22
    - OA-519
    - Opioid Peptides
    - P-glycoprotein
    - Pancreatic Oncofetal Antigen (POA)
    - Placental Lactogen
    - PR92

    - Proliferative Index, Ki-67
    - Px
    - RB Inactivation/Deletion
    - Ret
    - SCCL 175
    - Selectin
    - Sialic Acid
    - Sialyl SSEA-1/SLX
    - SN10
    - Somatostatin
    - TA-90
    - TABA
    - Tachykinin
    - TAG 12
    - TPS
    - Troponin
    - Tubulin
    - VCAM
    - VEGF
    - Villen and others
    C. Cancer Diagnostic Testing Instrumentation Review and Market Needs
    D. Current and Emerging Cancer Diagnostic Technologies
    1. Monoclonal and Polyclonal Antibodies
    2. Immunoassays
    3. Molecular Diagnostics
    4. Chromosome Analysis
    a. Chronic Myelogenous Leukemia (CML)
    b. Acute Myeloid Leukemia (AML)
    c. Acute Lymphoblastic Leukemia (ALL)
    d. Malignant Lymphomas Lymphoid Malignancies
    e. Chronic Lymphocytic Leukemia (CLL)
    f. Solid Cancers
    g. Chromosomal Translocation and Oncogenes
    5. Artificial Intelligence
    6. Flow Cytometry
    7. Two Dimensional Gel Electrophoresis (2-DGE)
    8. Biosensors
    9. Competing/Complementing Technologies
    E. Personal Testing

    VIII. Country Analysis
    A. Executive Summary
    B. Business Environment
    C. Market Structure
    D. Market Dynamics, Trends, Size and Growth
    - Volume Forecasts by Test and Market Segment
    - Sales Forecasts by Test and Market Segment
    - Major Supplier Sales and Market Shares
    IX. Competitive Profiles
    The report provides strategic assessments of over 30 leading cancer diagnostics market players
    and start-up companies with innovative technologies and products, including:
    - Abbott
    - Affymetrix
    - Beckman Coulter/Danaher/Cepheid
    - Becton Dickinson
    - bioMerieux
    - Bio-Rad
    - DiaSorin
    - Eiken Chemical
    - Elitech Group
    - Enzo Biochem
    - Fujifilm Wako
    - Fujirebio
    - Grifols
    - Hologic
    - Leica Biosystems
    - PerkinElmer
    - Qiagen
    - QuidelOrtho
    - Roche
    - Siemens Healthineers
    - Takara Bio
    - Thermo Fisher and others.

    List Of Tables

    Tumor Marker Classification
    Major Companies Developing or Marketing
    ACTH Tests
    Major Companies Developing or Marketing
    AFP Tests
    Major Companies Developing or Marketing
    Beta-2 Microglobulin Tests
    Major Companies Developing or Marketing
    CA 15-3/27.29 Tests
    Major Companies Developing or Marketing
    CA 19-9 Tests
    Major Companies Developing or Marketing
    CA 125 Tests
    Major Companies Developing or Marketing
    Calcitonin Tests
    Major Companies Developing or Marketing
    CEA Tests
    Major Companies Developing or Marketing
    Estrogen Receptor Tests
    Major Companies Developing or Marketing
    Progesterone Receptor Tests
    Major Companies Developing or Marketing
    Ferritin Tests
    Major Companies Developing or Marketing
    Gastrin Tests

    Major Companies Developing or Marketing
    HCG Tests

    Major Companies Developing or Marketing
    Insulin Tests

    Major Companies Developing or Marketing
    NSE Tests
    Major Companies Developing or Marketing
    Occult Blood Tests
    Major Companies Developing or Marketing
    PAP Smear/HPV Tests
    Major Companies Developing or Marketing
    PAP Tests
    Major Companies Developing or Marketing
    PSA Tests
    Major Companies Developing or Marketing
    Lymphocyte Subclassification Tests
    Biochemical Markers Potential Applications
    In Cancer Diagnosis
    Oncogenes Potential Applications
    In Cancer Diagnosis
    Major Companies Developing or Marketing
    Oncogene Tests
    Growth Factors Potential Applications
    In Cancer Diagnosis
    Colony Stimulating Factors Potential
    Applications in Cancer Diagnosis
    Lymphokines Potential Applications
    In Cancer Diagnosis

    Immunohistochemical Stains Potential
    Applications in Cancer Diagnosis
    Executive Summary Table: France, Hospital Cancer
    Diagnostic Test Volume and Sales Forecast
    France, Estimated Cancer Death Rates
    Per 100,000 Population
    France, Hospital Laboratories Performing
    Cancer Diagnostic Tests by Bed Size
    France, Hospital Laboratories Major Cancer
    Diagnostic Test Volume Forecast by Test
    France, Hospital Laboratories Cancer Diagnostics
    Sales Forecast by Test
    France, Total Cancer Diagnostics Sales
    By Major Supplier
    France, AFP Testing Market Diagnostics
    Sales by Major Supplier
    France, CA 15-3 Testing Market Diagnostics
    Sales by Major Supplier
    France, CA 19-9 Testing Market Diagnostics
    Sales by Major Supplier
    France, CA 125 Testing Market Diagnostics
    Sales by Major Supplier
    France, CEA Testing Market Diagnostics
    Sales by Major Supplier
    France, NSE Testing Market Diagnostics
    Sales by Major Supplier

    France, PAP Testing Market Diagnostics
    Sales by Major Supplier
    France, PSA Testing Market Diagnostics
    Sales by Major Supplier

    2024 U.S. Hospital Virology and Bacteriology Testing Market Supplier Shares and Strategies Volume and Sales Segment Forecasts Emerging Technologies Instrumentation and Opportunities

    2024 U.S. Hospital Virology and Bacteriology Testing Market: Supplier Shares and Strategies, Volume and Sales Segment Forecasts, Emerging Technologies, Instrumentation and OpportunitiesThis new report from contains 997 pages and 87

    USD 3750 View Report

    2024 U.K. Hospital Virology and Bacteriology Testing Market Supplier Shares and Strategies Volume and Sales Segment Forecasts Emerging Technologies Instrumentation and Opportunities

    2024 U.K. Hospital Virology and Bacteriology Testing Market: Supplier Shares and Strategies, Volume and Sales Segment Forecasts, Emerging Technologies, Instrumentation and OpportunitiesThis new report from contains 886 pages and 67

    USD 3500 View Report

    2024 France Hospital Virology and Bacteriology Testing Market Supplier Shares and Strategies Volume and Sales Segment Forecasts Emerging Technologies Instrumentation and Opportunities

    2024 France Hospital Virology and Bacteriology Testing Market: Supplier Shares and Strategies, Volume and Sales Segment Forecasts, Emerging Technologies, Instrumentation and Opportunities This new report from contains 897 pages and

    USD 3500 View Report

    2024 France Hepatitis Diagnostic Testing Markers Supplier Shares and Strategies Volume and Sales Segment Forecasts for Immunodiagnostic and Molecular Diagnostic Procedures--Hospitals Blood Banks Commercial Labs POC Locations

    2024 France Hepatitis Diagnostic Testing for 10 Markers: Supplier Shares and Strategies, Volume and Sales Segment Forecasts for Immunodiagnostic and Molecular Diagnostic Procedures--Hospitals, Blood Banks, Commercial Labs, POC LocationsThe report

    USD 2500 View Report

    Fill The Form For Sample Request

    Note : * Kindly provide us with your company id and get the sample reports at the earliest.

    There is no Reviews available